Brent Addington
Ray M. Allen, Jr.
Louis Caruso
Yaser Cheema
Mark A. Coppess
Jiang Cui
Todd D. Edwards
Jay Gardner
Richard Gordon
Steven S. Gubin
Paul Hess
David H. Holloway, Jr.
Jason Infeld
Christopher P Ingelmo
Eric E. Johnson
Jeffrey E. Kerlan
James E. Klemis
David H. Kraus
David Lan
Amit Malhotra
Justin May
Frank A. McGrew, III
Jennifer S. Morrow
Daniel Otten
Dharmesh S. Patel
Basil M. Paulus
William L. Russo
Holger P. Salazar
Joseph K. Samaha
Arsalan Shirwany
Stacy C. Smith
Darrell Sneed
Larry B. Spiotta
Bunker Stout
Arie Szatkowski
David C. Wolford
Walter Woody
Jawwad Yusuf
Gilbert Zoghbi
David H. Kraus, M.D., FACC
David H. Kraus


  • High School: White Station High School, Memphis, Tennessee, May, 1969
  • Undergraduate: University of Memphis, Memphis, Tennessee, May, 1973, B.S.
  • Graduate/Professional School: University of Tennessee Center for the Health Sciences, Memphis, Tennessee December, 1978, M.D.
  • Internship: Medicine Internship, City of Memphis and V. A. Hospital, Memphis, Tennessee, January, 1979-December, 1981
  • Residency: Medicine, Baptist Memorial Hospital, Memphis, Tennessee, January, 1979- December, 1981
  • Fellowship: Cardiology, University of Tennessee Center for the Health Sciences, Memphis, Tennessee, July, 1982 – June 30, 1984 
  • American Board of Internal Medicine, 1981
  • American Board of Internal Medicine-Cardiovascular Diseases, 1985
  • Tennessee, 1978
  • Mississippi, 1981
  • Arkansas, 1993
  • Missouri, 1999
  • HFSA National Advocacy Committee
Society Memberships
  • Memphis and Shelby County Medical Society
  • Tennessee Medical Association
  • American Medical Association
  • The Society of Critical Care Medicine
  • American College of Physicians-American Society of Internal Medicine
  • American College of Cardiology
Hospital Appointments
  • Associate Director, Cardiac Laboratories, Baptist Memorial Hospital, 1984-1987
  • Director, Echocardiography Laboratory, Baptist Memorial Hospital-East, 1984-1987
Hospital Affiliations
  • Baptist Memorial Hospital, Memphis, Tennessee, 1981-present
  • St. Francis Hospital, Memphis, Tennessee, 1981-present
  • Methodist Hospital, Memphis, Tennessee, 1983-present
  • Baptist Memorial Hospital-DeSoto, Southaven, Mississippi, 1979-present
Professional Experience
  • Memphis Heart Clinic (established July, 1999) – present
  • Memphis Heart Group, April, 1988 – July, 1999
  • The Cardiology Group of Memphis, PC, August, 1987 – April, 1988
  • Salky, Kraus and Addington, January, 1985 – August, 1987
  • David H. Kraus, M.D., 1984-1985
  • Baptist Memorial Hospital, Cardiology Department, 1984-1987
Research and other External Support
  • Schering Plough Pharmaceutical Research, A Double-Blind, Parallel Study Comparing The Antianginal Activity Of Three Doses Of Modified Transdermal Nitroglycerin And Placebo In Patients With Coronary Artery Disease, June, 1992 – November, 1993
  • Lorex Pharmaceutical Research, Efficacy And Safety Evaluation Of Three Doses Of Gits Verapamil In The Treatment Of Stable Angina Pectoris, July, 1992 - July, 1993
  • Bristol-Myers Squibb Pharmaceutical Research, Efficacy Of Fosinopril Sodium In Patients With Chronic Heart Failure Not Receiving Digoxin Therapy, June, 1992 – February, 1993
  • Syntex Pharmaceutical Research, A Double-Blind, Placebo Controlled, Extended Period, Crossover Study To Assess The Efficacy And Safety Of Three Dosing Regimens Of Randolazine In Patients With Chronic Stable Angina Pectoris, February, 1993 – May, 1993
  • Bristol-Myers Squibb Pharmaceutical Research, Evaluation Of The Hemodynamic Effects And Safety Of The Angiotensin II Antagonist SR47436 (Bristol-Myers Squibb 186294) In Patients With Heart Failure, April, 1994 – April, 1995
  • Bristol-Myers Squibb Pharmaceutical Research, The Effect Of Oral D-Sotalol On Mortality In Patients With Atherosclerotic Coronary Heart Disease and Left Ventricular Dysfunction-“SWORD”-Survival With Oral D-Sotalol, November, 1993 – October, 1994
  • Ciba Geigy Pharmaceutical Research, A Double-Blind, Randomized, Placebo-Controlled, Fixed Dose, Parallel Design Trial Of Ten Weeks Duration In Caucasian Patients With Mild To Moderate Hypertension Followed By An Open-Label Extension Of 98 Weeks Duration, March, 1993 – July 1995
  • Merck Research Laboratories, A Multicenter, Double-Blind Randomized, Parallel, Placebo-Controlled Study to Investigate The Effects Of Losartan Or The Exercise Capacity And Clinical Status Of Patients With Symptomatic Heart Failure-US, January, 1994 – December, 1995
  • Bristol-Myers Squibb Pharmaceutical Research, Effects Of Bristol-Myers-Squibb 180448 In Stable, Effort-Induced Angina Pectoris, July, 1994 – December, 1994
  • Astra, USA, Inc., MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure, A Double-Blind, Placebo-Controlled Survival Study with Metoprolol CR/LX In Patients With Decreased Ejection Fraction And Symptoms Of Heart Failure, May, 1997 – 1999
  • Parke-Davis/Pfizer, A 54-Week Open Label Assessment Of The Safety And Efficacy Profile Of Atorvastatin As Compared To Fluvastatin, Lovastatin, Simvastatin, And Pravastatin When Used To Optimally Control Primary Hypercholesterolemia (Type IIA) And Mixed Dyslipidemia (Type IIB), May, 1997 – January, 1999
  • Proctor & Gamble Pharmaceuticals, Inc., A Multi-Center Double-Blind, Placebo- Controlled, Parallel Design Clinical Trial To Assess The Efficacy And Safety Of 50 mg, 100 mg and 125 mg Of Aximilide Dihydrochloride Or The Prophylactic Treatment Of Symptomatic Atrial Fibrillation/Flutter And/Or Symptomatic Paroxysmal Supraventricular Tachycardia, October, 1996 – December, 1997
  • G. D. Searle & Company, Clinical Protocol For Efficacy And Safety Of Xemilofiban Hydrochloride (SC-54684A) Administration To Patients Undergoing Coronary Artery Or Stent Placement: Pivotal Trial IG7-96-02-017, IND# 46,247, August, 1997 – March, 1999
  • Proctor & Gamble Pharmaceuticals, Inc., A Double-Blind, Placebo-Controlled, Parallel Design Study To Determine the Effect Of 75 or 100 mg Of Orally Administered Aximilide Dihydrochloride Versus Placebo On Survival In Recent Post-Myocardial Infarction Patients At Risk Of Sudden Death, 1998-2001
  • Proctor & Gamble Pharmaceuticals, Inc., A Multi-Center, Double-Blind, Placebo- Controlled, Parallel Design Clinical Trial To Assess The Efficacy And Safety Of A Daily Oral Dose of 125 mg of Aximilide Dihydrochloride For The Prophylactic Treatment Of Symptomatic Atrial Fibrillation/Flutter And/Or Symptomatic Paroxysmal Supraventricular Tachycardia, July, 1998 – June, 1999
  • Duke Research And Henry Ford Coordinating Center, The 2nd SYMPHONY Trial, A Phase III, Multicenter, Internaltional, Randomized, Double-Blind, Aspirin-Controlled Trial To Evaluate The Efficacy And Safety Of Two Regimens With Xubix (Sibrafiban, RO48-3657), An Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, As Therapy For The Long Term Prevention Of Secondary Vascular Events In Patients After An Acute Coronary Syndrome, March, 1999 – June, 2000
  • Astra Pharmaceuticals, CHARM (Candesartan Cilexetil In Heart Failure: Assessment Of Reduction In Mortality and Morbidity), July, 1999 – 2003.
  • Bristol-Myers Squibb Pharmaceutical Research Institute, Omapatrilat Versus Enalapril Randomized Trial Of Utility In Reducing Events (OVERTURE), January, 2000 – 2003.
  • Proctor & Gamble Pharmaceuticals/Alexion Pharmaceuticals, A Randomized, Double- Blind, Placebo-Controlled Study Of Two Intravenous Dosing regimens Of H5G1.1-scFr In Patients With Acute Myocardial Infarction Undergoing Percutaneous Transluminal Coronary Angioplasty Reperfusion Therapy (COMMA), June, 2000.
  • Biovail Laboratories, Inc., A Double-Blind, Dose Response Study Of The Safety And Efficacy Of Diltiazem HCL Extended Release Capsules (G99) Dosed At Bedtime, Compared To Placebo And To G99 Dosed In The Morning In The Treatment Of Chronic, Stable, Exercise-Induced Angina, October, 2000.
  • Bristol-Myers Squibb Pharmaceutical Research Institute Pravastatin Or Atorvastatin Evaluation And Infection Therapy (PROVE IT), January, 2001 – 2003.
  • Guidant, Prospective, Randomized, Single-Blinded, Paralled-Group (two)arm), Multi- Center, Clinical Evaluation Of The Rx AchieveTM Drug Coated Coronary Stent System In The Treatment Of Patients With De Novo Native Coronary Artery Lesions, Protocol #01-345, December, 2001.
  • MedNova Ltd, CandioshieldTM Application Protects During Transluminal Intervention Of Vein Grafts By Reducing Emboli (Captive Pivoted Trial), December, 2001.
  • Boston Scientific Corporation, A Prospective Randomized Trial Evaluating The SympoitTM III Covered Stent System In Saphenous Vein Grafts, March, 2003.
  • G.D.Seaarle & Company, A Phase III International, Randomized, Double-Blind, Placebo- Controlled Trial Evaluating the Efficacy and Safety of Orbofiban in Patients with Unstable Coronary Syndromes, IND #49,380, Protocol #159-97-02-026, July, 1998.
  • F. Hoffman-LaRoche, Ltd., A Phase III, Multicenter, International, Randomized, Double- Blind, Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix™(Sibrafiban; RO48-3657), an Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, March, 1999.
  • Alexion Pharmaceuticals, Inc., A Randomized, Double-Blind, Placebo-Controlled Study of Two Intravenous Dosing Regimens of h5G1.1-scFv in Patients with Acute Myocardial Infarction Undergoing Thrombolytic Reperfusion Therapy, March, 2000.
  • Alexion Pharmaceuticals, Inc., A Randomized, Double-Blind, Placebo-Controlled Study of Two Intravenous Dosing Regimens of h5G1.1-scFv in Patients with Acute Myocardial Infarction Undergoing Percutaneous Transluminal Coronary Angioplasty Reperfusion Therapy, March, 2000.
  • Proctor & Gamble Pharmaceutical, Inc., Alive (A Double-Blind, Placebo-Controlled Parallel Design Study to Determine The Effect of 75 or 100 mg of Orally Administered Azimilide Dihydrochloride vs Placebo on Survival in Recent Post- Myocardial Infarction Patients at Risk of Sudden Death, October, 1997.
  • G. D. Searle & Co., Excite-Clinical Protocol for Efficacy and Safety of Zemilofiban Hydrochloride (SC-54684A) Administration to Patients Undergoing Coronary Angioplasty or Stent Placement Pivotal Trial, July, 1997.
  • Vasogen, Inc., A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo- Controlled Study of Efficacy And Safety Of Immune Modulation Therapy In Improving Walking Distance In patients With Intermittent Claudication Secondary To Peripheral Arterial Disease, March, 2003 – present.
  • Otsuka Maryland Research Institution, Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure, Protocol No. 156-03-236, November, 2003 – present.
  • Reliant Pharmaceuticals, Inc., (AFFECTS) Multicenter, Open-Label, Prospective Registry of Patients with Atrial Fibrillation Without Clinically Significant Structural Heart Disease or Atrial Fibrillation with Hypertension but neither LVH nor CAD, September 2004 – present.
  • Guidant, (PEGASUS-CRT) Randomized, Prospective, Single-Blinded, Three-Arm Study to Assess the Effect of a CRT Defibrillator (CRT-D) Programmed to DDD-70 or DDDR-40 Compared to DDD-40, December 2004 – present.
  • Novartis Pharmaceuticals, (NOVARTIS) An Eight Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Valsartan/HCTZ, compared to the combinations of Aliskiren/HCTZ and Valsartan/HCTZ in Patients with Essential Hypertension Not Adequately Responsive to HCTZ, Protocol No. CSPP100A2331, Fall, 2005 – present.
  • National Heart, Lung and Blood Institute-NIH/DHHS – Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist, A Multicenter, International, Randomized, Double-Blind, Placebo-Controlled Trial of the Aldosterone Antagonist – Spironolactone, Version – 1.4, Present.
  • “Effects of Losartan on Exercise Capacity, Morbidity and Mortality in Patients with Symptomatic Heart Failure.” Klinger G, Jaramillo N, Ikram H, Higginbotham J, Lang R, Kraus D, Washington L, Sharma D, Grossman W. Merck & Co., Inc., West Point, PA: Journal of the American College of Cardiology, Volume 29, 2 (supplement A), February, 1997; p. 205A.
  • “Hemodynamic Effects Of Dietary Sodium In Man.” Sullivan JM, Ratts TE, Taylor JC, Kraus DH, Barton BR, Patrick DR, Reed SW: Hypertension, Vol. 2, 4, July- August, 1989.
  • “Hemodynamic and Antihypertensive Effects of Captopril, An Orally Active Angiotensin Coverting Enzyme Inhibitor,” Sullivan JM, Ginsburg BA, Kraus DH, McKinstry DN, Muirhead EE: Hypertension, Vol. 1, 4, July-August, 1979; pp 397-401.
Consultation Services
  • Past Member of the Cardiology Advisory Committee for Physicians Data Corporation, Inc.
  • Past Member of the Allied HealthCare National Cardiology Advisory Panel
  • Present member XLHealth Physician Advisory Board State of Tennessee Heart Failure Committee

Home | Medical Services | Patient Education | Our Physicians | About Stern | Contact Us | Feedback | Privacy Statement
Allscripts link from Hospital

All Rights Reserved. Copyright 2006 The Stern Cardiovascular Foundation, P.A.
Stern Cardiovascular Foundation Website Developers